BioCentury
ARTICLE | Clinical News

Cabometyx cabozantinib: Phase II data

May 30, 2016 7:00 AM UTC

Top-line data from the open-label Phase II CABOSUN trial in 157 patients with previously untreated advanced RCC showed that first-line treatment with once-daily 60 mg oral Cabometyx met the primary endpoint of improving PFS vs. Sutent sunitinib. The trial was conducted by the Alliance for Clinical Trials in Oncology. ...